Litigation

Celgene Corp. v. Lotus Pharmaceutical Co., Ltd. et al.

settled

2:17-cv-06842

Filed
2017-09-06
Terminated
2019-03-30

Patents at issue (1)

Plaintiffs (1)

Summary

16-count complaint with the '740 patent among patents-in-suit; motion for judgment on the pleadings on REMS patents denied without prejudice Dec 14, 2018. Later settled March 30, 2019, with Lotus/Alvogen licensed to sell a limited-volume generic after March 2022.

Case overview & background

Plain-language overview of the case: parties, accused product, patents at issue, and why the suit matters.

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Key legal developments & outcome

Major rulings, motions, claim construction, settlements, and the present posture or final disposition.

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

In the news

What the press has reported about this case, summarized with links to the source articles.

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Plaintiff representatives

Counsel of record for the plaintiff(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Defendant representatives

Counsel of record for the defendant(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).